Biological therapy for psoriasis: infliximab, etanercept, adalimumab, efalizumab and alefacept

References

• Tutrone WD, Kagen MH, Barbagallo J, Weinberg JM. Biologic therapy for psoriasis: a brief history, II. Cutis68, 367–372 (2001).
   PubMedGoogle Scholar
• Singri P, West DP, Gordon KB. Biologic therapy for psoriasis: the new therapeutic frontier. Arch. Dermatol.138, 657–663 (2002).
   PubMed Web of Science ®Google Scholar
• Weinberg JM. An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasis. Clin. Ther.25, 2487–2505 (2003).
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Evans R, Li S et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J. Am. Acad. Dermatol.51, 534–542 (2004).
   PubMed Web of Science ®Google Scholar
• Reich K, Nestle FO, Papp K et al. EXPRESS study investigators. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a Phase III, multicentre, double-blind trial. Lancet366, 1367–1374 (2005).
   PubMed Web of Science ®Google Scholar
• Leonardi C, Powers JL, Matheson RT et al. Etanercept as monotherapy in patients with psoriasis. N. Engl. J. Med.349, 2014–2022 (2003).
   PubMed Web of Science ®Google Scholar
• Papp KA, Tyring S, Lahfa M et al. Etanercept Psoriasis Study Group. A global Phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br. J. Dermatol.152, 1304–1312 (2005).
   PubMed Web of Science ®Google Scholar
• Magliocco MA, Gottlieb AB. Etanercept therapy for patients with psoriatic arthritis and concurrent hepatitis C virus infection: report of 3 cases. J. Am. Acad. Dermatol.51, 580–584 (2004).
   PubMed Web of Science ®Google Scholar
• Adalimumab (HUMIRA) for rheumatoid arthritis. Med. Lett. Drugs Ther.45, 25–27 (2003).
   PubMedGoogle Scholar
• Gordon KB, Leonardi C, Menter MA, Langley R, Chen DM. Adalimumab efficacy and safety in patients with moderate to severe chronic plaque psoriasis: preliminary findings from a 12-week dose-ranging trial. Presented at: American Academy of Dermatology, 62nd Annual Meeting, WA, USA, February 6–11 (2004) (Poster 2).
   Google Scholar
• Langley R, Leonardi C, Toth D, Hoofman R. Long-term safety and efficacy of adalimumab in the treatment of moderate to severe chronic plaque psoriasis. Presented at: American Academy of Dermatology, 63rd Annual Meeting, LA, USA, February 18–22 (2005) (Poster 8).
   Google Scholar
• Lebwohl M. New developments in the treatment of psoriasis. Arch. Dermatol.138, 686–688 (2002).
   PubMed Web of Science ®Google Scholar
• Keane J, Gershon S, Wise RP et al. Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N. Engl. J. Med.345, 1098–1104 (2001).
   PubMed Web of Science ®Google Scholar
• Bresnihan B, Cunnane G. Infection complications associated with the use of biologic agents. Rheum. Dis. Clin. North Am.29, 185–202 (2003).
   PubMed Web of Science ®Google Scholar
• Gardam MA, Keystone EC, Menzies R et al. Antitumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect. Dis.3, 148–155 (2003).
   PubMed Web of Science ®Google Scholar
• Hamilton CD. Infectious complications of treatment with biologic agents. Curr. Opin. Rheumatol.16, 393–398 (2004).
   PubMed Web of Science ®Google Scholar
• Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum.46, 3151–3158 (2002).
   PubMed Web of Science ®Google Scholar
• Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and antitumor necrosis factor therapy in 18,572 patients. Arthritis Rheum.50, 1740–1751 (2004).
   PubMed Web of Science ®Google Scholar
• Adams AE, Zwicker J, Curiel C et al. Aggressive cutaneous T-cell lymphomas after TNF α blockade. J. Am. Acad. Dermatol.51, 660–662 (2004).
   PubMed Web of Science ®Google Scholar
• Mohan N, Edwards ET, Cupps TR et al. Demyelination occurring during antitumor necrosis factor α therapy for inflammatory arthritides. Arthritis Rheum.44, 2862–2869 (2001).
   PubMed Web of Science ®Google Scholar
• Kwon HJ, Cote TR, Cuffe MS, Kramer JM, Braun MM. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann. Intern. Med.138, 807–811 (2003).
   PubMed Web of Science ®Google Scholar
• Debandt M, Vittecoq O, Descamps V, Le Loet X, Meyer O. Anti-TNF-α-induced systemic lupus syndrome. Clin. Rheumatol.22, 56–61 (2003).
   PubMed Web of Science ®Google Scholar
• Watts RA. Musculoskeletal and systemic reactions to biological therapeutic agents. Curr. Opin. Rheumatol.12, 49–52 (2000).
   PubMed Web of Science ®Google Scholar
• Maini R, St Clair EW, Breedveld F et al. (ATTRACT Study Group). Infliximab (chimeric antitumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised Phase III trial. Lancet354, 1932–1939 (1999).
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, D’Haens G, Targan S et al. Efficacy and safety of retreatment with antitumor necrosis factor antibody (infliximab) to maintain remission in Crohn’s disease. Gastroenterology117, 761–769 (1999).
   PubMed Web of Science ®Google Scholar
• Shakoor N, Michalska M, Harris CA, Block JA. Drug-induced systemic lupus erythematosus associated with etanercept therapy (letter). Lancet359, 579–580 (2002).
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Tyring SK, Hamilton TK et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N. Engl. J. Med.349, 2004–2013 (2003).
   PubMed Web of Science ®Google Scholar
• Gordon KB, Papp KA, Hamilton TK et al. Efalizumab Study Group. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA290, 3073–3080 (2003).
   PubMed Web of Science ®Google Scholar
• Menter A, Kardatzke D, Rundle AC, Kwon P, Garovoy MR, Leonardi CL. Incidence and prevention of rebound upon efalizumab discontinuation. Presented at: 10th International Psoriasis Symposium, Toronto, Canada, June 10–13 (2004).
   Google Scholar
• Toth DP, Papp KA. Managing recurrence of psoriasis following abrupt withdrawal form efalizumab therapy. Presented at: 10th International Psoriasis Symposium, Toronto, Canada, June 10–13 (2004).
   Google Scholar
• Cather JC, Menter A. Efalizumab: continuous therapy for chronic psoriasis. Expert Opin. Biol. Ther.5, 393–403 (2005).
   PubMed Web of Science ®Google Scholar
• RAPTIVA® (efalizumab), package insert. Genentech, Inc., CA, USA (2005).
   Google Scholar
• Lebwohl M, Christophers E, Langley R et al. An international, randomized, double-blind, placebo-controlled Phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch. Dermatol.139, 719–727 (2003).
   PubMed Web of Science ®Google Scholar
• Krueger GG, Ellis CN. Alefacept therapy produces remission for patients with chronic plaque psoriasis. Br. J. Dermatol.148, 784–788 (2003).
   PubMed Web of Science ®Google Scholar
• Ellis CN, Krueger GG. Treatment of chronic plaque psoriasis by selective targeting of memory effector T-lymphocytes. N. Engl. J. Med.345, 248–255 (2001).
   PubMed Web of Science ®Google Scholar
• Gribetz CH, Blum R, Brady C, Cohen S, Lebwohl M. Safety and efficacy of an extended course (16 weeks) of alefacept in the treatment of chronic plaque psoriasis. Presented at: Summer Academy 2004 of the American Academy of Dermatology, NY, USA, July 28–August 1 (2004) (Poster 74).
   Google Scholar
• AMEVIVE® (alefacept), package insert. Biogen, Inc., MA, USA (2005).
   Google Scholar